Targeting Serine in Cancer: Is Two Better Than One? Academic Article uri icon

Overview

abstract

  • Several recent preclinical studies have demonstrated that simultaneously blocking exogenous and endogenous sources of serine in malignant cells mediates superior anticancer effects as compared with limiting either source alone. Here, we critically summarize key developments in targeting serine to treat cancer and discuss persisting challenges for implementing such a therapeutic approach in patients.

publication date

  • July 1, 2021

Research

keywords

  • Antimetabolites, Antineoplastic
  • Diet, Protein-Restricted
  • Neoplasms
  • Serine

Identity

PubMed Central ID

  • PMC9097339

Scopus Document Identifier

  • 85109488761

Digital Object Identifier (DOI)

  • 10.1016/j.trecan.2021.06.004

PubMed ID

  • 34219053

Additional Document Info

volume

  • 7

issue

  • 8